Paid Clinical Trials in Indianapolis, IN

As of July 2026, 861 paid clinical trials are recruiting in Indianapolis, Indiana. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 31, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

766 clinical trials

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

for Chronic Obstructive Pulmonary Disease

Drug: Lunsekimig

Sites in Indianapolis +65 more locations

Sponsor: Sanofi

Sex: All·Age: 40 - 80

Code: NCT07190209·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

for Cervical Cancer

Sites in Indianapolis +127 more locations

Sponsor: Pfizer

Sex: Female·Age: 18+

Code: NCT06952660·Phase 4·Recruiting·Listed May 2025

Apply to this trial

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

for Renal Cell Carcinoma (RCC)

Sites in Indianapolis +43 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for Breast Neoplasms

Sites in Indianapolis, Fort Wayne +58 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06966700·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

for Acne

Sites in Indianapolis +78 more locations

Sponsor: Sanofi Pasteur, a Sanofi Company

Sex: All·Age: 18 - 45

Code: NCT06316297·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

for Small-cell Lung Cancer

Drug: Durvalumab

Sites in Indianapolis +49 more locations

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in Indianapolis, Fort Wayne +84 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

for Proteinuric Kidney Disease

Sites in Indianapolis, Fort Wayne +165 more locations

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 10 - 65

Code: NCT05312879·Phase 2, Phase 3·Recruiting·Listed Apr 2022

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

Drug: Amivantamab

Sites in Indianapolis +67 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

for Early Breast Cancer

Drug: Ribociclib

Sites in Indianapolis +84 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

for Multiple Myeloma

Drug: Elranatamab

Sites in Indianapolis +94 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06152575·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in Indianapolis, Fort Wayne +86 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

Drug: sigvotatug vedotin

Sites in Indianapolis, Fort Wayne +102 more locations

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting·Listed May 2020

Apply to this trial

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

for Heart Failure

Drug: Empagliflozin

Sites in Indianapolis, Richmond +97 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06935370·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

for Chronic Kidney Disease

Drug: Empagliflozin

Sites in Indianapolis +29 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 2 - 17

Code: NCT07107945·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

for Advanced Cancer

Sites in Indianapolis +37 more locations

Sponsor: Artios Pharma Ltd

Sex: All·Age: 18+

Code: NCT04657068·Phase 1, Phase 2·Recruiting·Listed Dec 2020

Apply to this trial

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

for Heart Failure With Preserved Ejection Fraction

Sites in Indianapolis, Richmond +108 more locations

Sponsor: Amgen

Sex: All·Age: 18 - 99

Code: NCT07037459·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

for Crohn's Disease

Drug: Tulisokibart

Sites in Indianapolis +70 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 16 - 80

Code: NCT06430801·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

Sites in Indianapolis +77 more locations

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

Sites in Indianapolis, Fort Wayne +59 more locations

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

for Diabetes Mellitus, Type 2

Sites in Indianapolis +122 more locations

Sponsor: Cleerly, Inc.

Sex: All·Age: 55+·Accepts healthy volunteers

Code: NCT06112418·Recruiting·Listed Nov 2023

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

Sites in Indianapolis +51 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

for NonSegmental Vitiligo

Drug: Ruxolitinib

Sites in Indianapolis +68 more locations

Sponsor: Incyte Corporation

Sex: All·Age: 2 - 11

Code: NCT06548360·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

for Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

Sites in Indianapolis +36 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18 - 75

Code: NCT05519475·Phase 2·Recruiting·Listed Aug 2022

Apply to this trial

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

for Lumbar Spinal Stenosis

Sites in Indianapolis, Greenwood +2341 more locations

Sponsor: Stryker Instruments

Sex: All·Age: 18+

Code: NCT03072927·Recruiting·Listed Mar 2017

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

Sites in Indianapolis, Fort Wayne +64 more locations

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

for Heart Failure

Drug: Empagliflozin

Sites in Indianapolis, Richmond +93 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06424288·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Assessment of CCM in HF With Higher Ejection Fraction

for Heart Failure

Sites in Indianapolis +75 more locations

Sponsor: Impulse Dynamics

Sex: All·Age: 18+

Code: NCT05064709·Recruiting·Listed Oct 2021

Apply to this trial

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

for Alopecia Areata

Drug: Upadacitinib

Sites in Indianapolis +39 more locations

Sponsor: AbbVie

Sex: All·Age: 12 - 63

Code: NCT06012240·Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

Drug: Intismeran autogene

Sites in Indianapolis +48 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

for Colorectal Cancer

Sites in Indianapolis +31 more locations

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT06562543·Phase 4·Recruiting·Listed Aug 2024

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

Drug: Zongertinib

Sites in Indianapolis +25 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for Moderately to Severely Active Crohns Disease

Drug: Afimkibart

Sites in Indianapolis, New Albany +90 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 16 - 80

Code: NCT06819878·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

for Solid Cancer

Sites in Indianapolis +24 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06161025·Phase 2, Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Drug: Etentamig

Sites in Indianapolis, Fort Wayne +25 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT05650632·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

for Urinary Bladder Neoplasms

Sites in Indianapolis +40 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05614739·Phase 1·Recruiting·Listed Nov 2022

Apply to this trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

Sites in Indianapolis +27 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting·Listed Jan 2022

Apply to this trial

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

for Crohn's Disease

Sites in Indianapolis +55 more locations

Sponsor: AbbVie

Sex: All·Age: 18 - 75

Code: NCT06548542·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

for Peripheral Vascular Diseases

Sites in Indianapolis +37 more locations

Sponsor: Boston Scientific Corporation

Sex: All·Age: 18+

Code: NCT04674969·Recruiting·Listed Dec 2020

Apply to this trial

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

for Plaque Psoriasis

Drug: Deucravacitinib

Sites in Indianapolis +43 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 12 - 17

Code: NCT06979453·Phase 3·Recruiting·Listed May 2025

Apply to this trial